Esteve Pharmaceuticals

Part of Esteve Healthcare

CompanySpainFounded 1936

Esteve Pharmaceuticals develops one asset, in phase 3 (Co-crystal E-58425 in acute post surgical pain). Mostly small molecule acting on inflammation, PTGS2 and SLC6A2; based in Spain, founded in 1936.

1
Asset
Furthest stage: Phase 3; 1
Trial: 0
Signals

Pipeline

1

Co-crystal E-58425
Co-crystal of tramadol and celecoxib providing dual opioid and anti-inflammatory analgesia via COX-2 and mu-opioid receptor modulation
Phase 3, Small molecule, Inflammation, PTGS2, acute post surgical pain

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms6
Trials2
Similar companies6